Amgen Inc. $AMGN Shares Bought by American Investment Services Inc.

American Investment Services Inc. increased its position in Amgen Inc. (NASDAQ:AMGN) by 45.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,719 shares of the medical research company’s stock after purchasing an additional 3,049 shares during the quarter. American Investment Services Inc.’s holdings in Amgen were worth $2,743,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Athena Investment Management increased its stake in Amgen by 3.2% during the 3rd quarter. Athena Investment Management now owns 3,874 shares of the medical research company’s stock worth $1,093,000 after buying an additional 120 shares during the period. Invesco Ltd. raised its position in shares of Amgen by 6.6% in the 3rd quarter. Invesco Ltd. now owns 4,467,287 shares of the medical research company’s stock valued at $1,260,668,000 after purchasing an additional 277,031 shares in the last quarter. Seven Mile Advisory boosted its stake in shares of Amgen by 80.6% during the 3rd quarter. Seven Mile Advisory now owns 1,539 shares of the medical research company’s stock valued at $434,000 after buying an additional 687 shares during the last quarter. White Lighthouse Investment Management Inc. boosted its stake in shares of Amgen by 1.3% during the 3rd quarter. White Lighthouse Investment Management Inc. now owns 3,465 shares of the medical research company’s stock valued at $978,000 after buying an additional 46 shares during the last quarter. Finally, Kepler Cheuvreux Suisse SA acquired a new stake in shares of Amgen during the third quarter worth approximately $5,003,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on AMGN shares. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research note on Thursday, February 5th. Mizuho increased their price target on shares of Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Morgan Stanley lifted their price target on Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 4th. Freedom Capital cut Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 12th. Finally, Wells Fargo & Company increased their target price on Amgen from $325.00 to $375.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Amgen currently has an average rating of “Hold” and a consensus target price of $354.00.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: MariTide and osteoporosis drug sales cited as a key driver of recent investor enthusiasm; analysts/coverage note product momentum that helped push earlier gains. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Operational/production support: Rapid Micro Biosystems reported that Amgen expanded a global Growth Direct system rollout (multi‑system order), signaling investments in manufacturing capacity and process efficiency. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Positive Sentiment: Institutional buying/positioning: Amgen is highlighted as a holding in a large income fund, reflecting demand from dividend/income managers seeking defensive, high‑yield large caps. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Macro/sector support: Prominent market commentators have endorsed large‑cap biotech as resilient growth plays, which supports longer‑term investor interest. Josh Brown: Biotech growth stocks immune to disruption risk
• Neutral Sentiment: Company presentation: A recent Leerink Global Healthcare conference transcript provides updated management commentary — useful for gauging near‑term guidance and pipeline cadence but not an immediate catalyst by itself. Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Valuation discussion: Coverage pieces assessing whether AMGN is mispriced highlight mixed returns vs. peers — useful context for investors but not a direct price mover. Assessing Whether Amgen (AMGN) Shares Look Mispriced After Recent Mixed Returns
• Neutral Sentiment: Short‑interest data appears to contain errors (reports show zero shares/NaN changes and a 0.0 days-to-cover figure); there’s no clear evidence of meaningful short pressure at present.
• Negative Sentiment: Analyst stance: Jefferies initiated coverage with a Hold recommendation, which can cap momentum relative to a Buy/Outperform narrative and may contribute to near‑term selling pressure. Jefferies initiates coverage of Amgen (AMGN) with hold recommendation

Amgen Trading Down 2.6%

Shares of NASDAQ:AMGN opened at $367.79 on Friday. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The company has a market cap of $198.26 billion, a PE ratio of 25.85, a P/E/G ratio of 3.75 and a beta of 0.45. The company’s 50-day moving average price is $356.96 and its 200 day moving average price is $324.63. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the previous year, the firm posted $5.31 EPS. The firm’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. Amgen’s dividend payout ratio (DPR) is 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.